We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

77 hedge funds and large institutions have $616M invested in Arbutus Biopharma in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

841% more capital invested

Capital invested by funds: $65.5M → $616M (+$550M)

173% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $3.78M

156% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 18

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

57% more funds holding

Funds holding: 49 → 77 (+28)

Holders
77
Holders Change
+28
Holders Change %
+57.14%
% of All Funds
2.05%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
46
Increased
17
Reduced
8
Closed
18
Calls
$10.3M
Puts
$3.78M
Net Calls
+$6.52M
Net Calls Change
+$1.49M

Top Buyers

1
QF
QVT Financial
New York
+$328M
2
RCM
RA Capital Management
Massachusetts
+$55.6M
3
AWG
Alpha Wave Global
New York
+$45.5M
4
BRC
Blue Ridge Capital
New York
+$34.8M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$33.3M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$6.22M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.95M
3
OSAM
O'Shaughnessy Asset Management
Connecticut
-$1.89M
4
NCCM
Nine Chapters Capital Management
New Jersey
-$1.11M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
51
Alyeska Investment Group
Illinois
$375K +$440K +21,476 New
AC
52
Ascend Capital
California
$349K +$410K +20,000 New
BCM
53
Bourgeon Capital Management
Connecticut
$349K +$410K +20,000 New
SCM
54
Sterling Capital Management
North Carolina
$249K +$292K +14,263 New
Geode Capital Management
55
Geode Capital Management
Massachusetts
$212K +$250K +12,187 New
Fidelity Investments
56
Fidelity Investments
Massachusetts
$203K +$238K +11,600 New
Jane Street
57
Jane Street
New York
$178K +$209K +10,200 New
Simplex Trading
58
Simplex Trading
Illinois
$150K +$177K +8,647 New
AIG
59
American International Group
New York
$143K +$85K +4,150 +102%
Ohio Public Employees Retirement System (OPERS)
60
Ohio Public Employees Retirement System (OPERS)
Ohio
$98K +$115K +5,600 New
TRCT
61
Tower Research Capital (TRC)
New York
$93K +$92.2K +4,500 +554%
PMAM
62
Picton Mahoney Asset Management
Ontario, Canada
$56K +$65.5K +3,200 New
Wells Fargo
63
Wells Fargo
California
$48K +$47.1K +2,300 +500%
UBS Group
64
UBS Group
Switzerland
$15K -$20.4K -995 -53%
AllianceBernstein
65
AllianceBernstein
Tennessee
$9K – – –
QT
66
Quantbot Technologies
New York
$8K +$10.2K +500 New
BIT
67
BlackRock Institutional Trust
California
$7K -$161K -7,837 -95%
PNC Financial Services Group
68
PNC Financial Services Group
Pennsylvania
$7K -$10.2K -500 -56%
LTFS
69
Ladenburg Thalmann Financial Services
Florida
$5K +$6.14K +300 New
NFG
70
Next Financial Group
Texas
$3K – – –
US Bancorp
71
US Bancorp
Minnesota
$3K – – –
Bank of America
72
Bank of America
North Carolina
$2K -$5.82K -284 -71%
BPBT
73
Boston Private Bank & Trust
Massachusetts
$2K – – –
CSS
74
Cubist Systematic Strategies
Connecticut
$2K +$2.05K +100 New
Creative Planning
75
Creative Planning
Kansas
$1K – – –
1 2
3
4

ABUS Hedge Fund Activity: Q1 2015 in Review

77 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2015, worth a combined $616M — up 841% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ABUS positions and 18 closed out — a net gain of 28 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was QVT Financial, opening a new position worth an estimated $328M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.22M.

  • 77 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2015, up from 49 in Q4 2014.
  • Funds reported $616M of Arbutus Biopharma stock for Q1 2015, up 841% quarter-over-quarter.
  • 46 funds opened new Arbutus Biopharma positions in Q1 2015 and 18 closed out, a net change of +28 holders.
  • The largest Arbutus Biopharma buyer in Q1 2015 was QVT Financial, an estimated $328M added.
  • The largest Arbutus Biopharma seller in Q1 2015 was Baker Bros. Advisors, an estimated $6.22M sold.

Based on aggregated 13F filings for Q1 2015.